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A bs tr ac t
Background
To assess potentially elevated cardiovascular risk related to new antihyperglycemic 
drugs in patients with type 2 diabetes, regulatory agencies require a comprehensive 
evaluation of the cardiovascular safety profile of new antidiabetic therapies. We 
assessed cardiovascular outcomes with alogliptin, a new inhibitor of dipeptidyl 
peptidase 4 (DPP-4), as compared with placebo in patients with type 2 diabetes who 
had had a recent acute coronary syndrome.
Methods
We randomly assigned patients with type 2 diabetes and either an acute myocar-
dial infarction or unstable angina requiring hospitalization within the previous 15 
to 90 days to receive alogliptin or placebo in addition to existing antihyperglycemic 
and cardiovascular drug therapy. The study design was a double-blind, noninferiority 
trial with a prespecified noninferiority margin of 1.3 for the hazard ratio for the 
primary end point of a composite of death from cardiovascular causes, nonfatal myo-
cardial infarction, or nonfatal stroke.
Results
A total of 5380 patients underwent randomization and were followed for up to 40 
months (median, 18 months). A primary end-point event occurred in 305 patients 
assigned to alogliptin (11.3%) and in 316 patients assigned to placebo (11.8%) (haz-
ard ratio, 0.96; upper boundary of the one-sided repeated confidence interval, 1.16; 
P<0.001 for noninferiority). Glycated hemoglobin levels were significantly lower 
with alogliptin than with placebo (mean difference, −0.36 percentage points; 
P<0.001). Incidences of hypoglycemia, cancer, pancreatitis, and initiation of dialysis 
were similar with alogliptin and placebo.
Conclusions
Among patients with type 2 diabetes who had had a recent acute coronary syn-
drome, the rates of major adverse cardiovascular events were not increased with the 
DPP-4 inhibitor alogliptin as compared with placebo. (Funded by Takeda Develop-
ment Center Americas; EXAMINE ClinicalTrials.gov number, NCT00968708.)
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T ype 2 diabetes is associated with both microvascular and macrovascular complications.1 The risk of cardiovascular 
disease is two to four times as high in people 
with diabetes as in people without diabetes.1,2 
Improved glycemic control can reduce the risk of 
many microvascular complications of diabetes,3 
but studies have not shown a favorable effect of 
glycemic control in reducing macrovascular 
events in patients with type 2 diabetes.4,5 Con-
cerns regarding adverse cardiovascular outcomes 
with antidiabetic agents6,7 prompted the Food 
and Drug Administration (FDA) to issue guid-
ance in December 2008 that included specific 
requirements for cardiovascular safety assess-
ment before and after the approval of new anti-
diabetic therapies.8 Regulatory agencies in other 
countries have adopted similar policies.
Alogliptin is a selective inhibitor of dipeptidyl 
peptidase 4 (DPP-4) that is approved for the 
treatment of type 2 diabetes.9,10 By preventing 
the rapid degradation of glucagon-like peptide 1 
(GLP-1) through inhibition of DPP-4, alogliptin 
enhances pancreatic insulin secretion and sup-
presses pancreatic glucagon secretion, thus re-
ducing blood glucose levels.10 During the clinical 
development program, no imbalance in cardio-
vascular events was noted among 4168 patients 
with type 2 diabetes who received alogliptin, 691 
patients who received placebo, and 1169 patients 
who received active comparators.11 Given the 
low cardiovascular-risk profile of the patient 
population and the low event rate, the cardiovas-
cular safety in patients at high cardiovascular 
risk could not be assessed. We conducted the 
Examination of Cardiovascular Outcomes with 
Alogliptin versus Standard of Care (EXAMINE) 
trial to determine whether alogliptin is noninfe-
rior to placebo with respect to major cardiovas-
cular events in patients with type 2 diabetes who 
are at very high cardiovascular risk — those 
with recent acute coronary syndromes.
Me thods
Study Design
The EXAMINE trial was a multicenter, random-
ized, double-blind trial. The details of the design 
have been published previously.12 The content of 
the manuscript is consistent with the research 
protocol, which is available with the full text of 
this article at NEJM.org. The steering committee, 
consisting of academic members and three non-
voting representatives of the sponsor (Takeda De-
velopment Center Americas), designed and over-
saw the conduct of the trial. An independent data 
and safety monitoring committee monitored the 
trial and had access to the unblinded data. The 
statistical analysis was performed by Pharmaceu-
tical Product Development, a contract research 
organization, in collaboration with investigators 
at the academic centers and the sponsor, all of 
whom had full access to the final study data. The 
sponsor provided alogliptin at no cost and coordi-
nated the data management. The chair of the 
steering committee (the first author) and other 
members of the committee who are academic 
authors wrote all drafts of the manuscript and 
vouch for the accuracy and completeness of the re-
ported data. MedLogix Communications provided 
assistance with the figures, with funding from the 
sponsor. The appropriate national and institutional 
regulatory authorities and ethics committees ap-
proved the study design, and all participants pro-
vided written informed consent.
Study Patients
Patients were eligible for enrollment if they had 
received a diagnosis of type 2 diabetes mellitus, 
were receiving antidiabetic therapy (other than a 
DPP-4 inhibitor or GLP-1 analogue), and had had 
an acute coronary syndrome within 15 to 90 days 
before randomization. Further criteria for the di-
agnosis of type 2 diabetes included a glycated 
hemoglobin level of 6.5 to 11.0% at screening, or 
if the antidiabetic regimen included insulin, a 
glycated hemoglobin level of 7.0 to 11.0%. Acute 
coronary syndromes included acute myocardial 
infarction and unstable angina requiring hospital-
ization, as defined previously.12 Major exclusion 
criteria were a diagnosis of type 1 diabetes, un-
stable cardiac disorders (e.g., New York Heart As-
sociation class IV heart failure, refractory angina, 
uncontrolled arrhythmias, critical valvular heart 
disease, or severe uncontrolled hypertension), and 
dialysis within 14 days before screening.
Study Drugs and Procedures
Patients were randomly assigned to receive alo-
gliptin or placebo, administered in a double-
blind fashion, in addition to standard-of-care 
treatment for type 2 diabetes mellitus. Through-
out the study, patients were required to receive 
standard-of-care treatment for type 2 diabetes 
and cardiovascular risk factors according to re-
gional guidelines. Because alogliptin is cleared 
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by the kidney, the doses of alogliptin (and match-
ing placebo) were modified according to kidney 
function at the time of randomization and during 
the postrandomization period. The daily doses of 
the study drug were as follows: 25 mg in patients 
with an estimated glomerular filtration rate (GFR), 
calculated with the use of the Modification of Diet 
in Renal Disease formula, of at least 60 ml per 
minute per 1.73 m2 of body-surface area; 12.5 mg 
in patients with an estimated GFR of 30 to less 
than 60 ml per minute per 1.73 m2; and 6.25 mg in 
patients with an estimated GFR of less than 30 ml 
per minute per 1.73 m2.
Outpatient visits were scheduled at the time 
of screening, at randomization, and at 1, 3, 6, 9, 
and 12 months after randomization during the 
first year of the study and every 4 months during 
subsequent years of participation. If patients 
declined to return for study visits, information 
was obtained during telephone contacts, but this 
was not the preferred approach nor was it rec-
ommended to the sites.
End Points
The primary end point was a composite of death 
from cardiovascular causes, nonfatal myocardial 
infarction, or nonfatal stroke. The principal sec-
ondary safety end point was the primary compos-
ite end point with the addition of urgent revascu-
larization due to unstable angina within 24 hours 
after hospital admission (Table S1 in the Supple-
mentary Appendix, available at NEJM.org).12,13 Ex-
ploratory end points included death from cardio-
vascular causes and death from any cause. The 
consistency of effects with respect to the primary 
end point was explored in a variety of subgroups 
without adjustment for multiple comparisons. Ad-
ditional safety end points included angioedema, 
hypoglycemia, pancreatitis, cancer, and the re-
sults of laboratory testing. An independent central 
adjudication committee adjudicated all suspected 
primary end-point events and other cardiovascular 
end points, as well as all deaths.
Statistical Analysis
Cox proportional-hazards models were used to 
analyze the time to the first occurrence of a pri-
mary or secondary end-point event among all 
randomly assigned patients, with stratification 
according to geographic region and renal func-
tion at baseline. Initial group sequential analyses 
were planned after 80, 100, 125, and 150 adjudi-
cated primary end-point events occurred, with an 
O’Brien and Fleming–type spending function14 
used to preserve an overall alpha of 2.5% for rul-
ing out a hazard ratio of more than 1.8. If each 
of the four initial group sequential analyses 
failed to rule out an upper boundary of 1.8, the 
trial would be stopped because of futility. If one 
of these analyses ruled out an upper boundary of 
1.8, the trial was designed to continue and simi-
lar analyses were to be performed after 550 and 
650 adjudicated primary end-point events oc-
curred, with a separate alpha spending function 
used to maintain a 2.5% overall alpha for ruling 
out a hazard ratio of more than 1.3 (1.0% and 
1.5% alpha spent after 550 and 650 events, re-
spectively). Additional tests for statistical superi-
ority of alogliptin with respect to the primary 
and secondary end points would be conducted if 
a hazard ratio of more than 1.3 was ruled out 
with the use of the same alpha spending func-
tion. If noninferiority was declared but the con-
ditional power for superiority at 650 events on 
the basis of the 550-event interim analysis was 
20% or lower, the study would be stopped. We 
calculated that with a sample of 5400 patients, 
the study would have 91% power to determine 
the noninferiority of alogliptin to placebo for the 
1.8 (initial) and 1.3 margins, with the assump-
tion of a true hazard ratio of 1.0 and overall one-
sided significance levels of 2.5%.
For each group sequential analysis, the statisti-
cal analysis plan specified that the upper bound-
ary of a one-sided repeated confidence interval for 
the hazard ratio (alogliptin to placebo) would be 
calculated with the use of the critical value ob-
tained from the appropriate spending function 
and compared with the appropriate noninferior-
ity margins.14,15 Each analysis was to be conducted 
by an independent statistician and reviewed by the 
data and safety monitoring committee. The first 
group sequential analysis, performed after 83 
adjudicated primary end-point events had oc-
curred, showed that the upper boundary of the 
one-sided repeated confidence interval for the haz-
ard ratio was 1.51. This information was com-
municated to the data and safety monitoring 
committee by the independent statistician, and 
after the assessment by that committee, the analy-
sis was submitted to the regulatory authorities 
for review. To protect the overall statistical va-
lidity and integrity of the study, persons associ-
ated with this analysis were not involved in 
subsequent preparation and review of blinded 
data, nor were they involved in ongoing study 
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Table 1. Baseline Characteristics of the Patients, According to Study Group.*
Characteristic
Placebo  
(N = 2679)
Alogliptin  
(N = 2701)
Median age — yr 61.0 61.0
Age ≥65 yr — no. (%) 934 (34.9) 973 (36.0)
Male sex — no. (%) 1823 (68.0) 1828 (67.7)
Duration of diabetes — yr
Median 7.3 7.1
Range 2.8–13.7 2.6–13.8
Glycated hemoglobin — % 8.0±1.1 8.0±1.1
Body weight — kg
Median 80.0 80.2
Range 35.5–196.3 36.0–185.0
Body-mass index†
Median 28.7 28.7
Range 15.6–68.3 15.7–55.9
Race or ethnic group — no. (%)‡
White 1943 (72.5) 1966 (72.8)
Black 115 (4.3) 101 (3.7)
Asian 542 (20.2) 547 (20.3)
Native American 54 (2.0) 56 (2.1)
Other 25 (0.9) 31 (1.1)
Region of world — no. (%)
United States and Canada 426 (15.9) 427 (15.8)
Western Europe, Australia, New Zealand, and Middle East 303 (11.3) 313 (11.6)
Central and South America and Mexico 693 (25.9) 700 (25.9)
Eastern Europe and Africa 753 (28.1) 755 (28.0)
Asia and Pacific Islands 504 (18.8) 506 (18.7)
Cardiovascular risk factors and history — no. (%)
Current smoker 383 (14.3) 351 (13.0)
Hypertension 2240 (83.6) 2229 (82.5)
Myocardial infarction§ 2345 (87.5) 2389 (88.4)
Percutaneous coronary intervention§ 1683 (62.8) 1689 (62.5)
Coronary-artery bypass grafting§ 341 (12.7) 347 (12.8)
Congestive heart failure 744 (27.8) 757 (28.0)
Stroke 193 (7.2) 195 (7.2)
Peripheral arterial disease 252 (9.4) 262 (9.7)
Estimated glomerular filtration rate¶
Median — ml/min/1.73 m2 71.2 71.1
≥60 ml/min/1.73 m2 — no. (%) 1886 (70.4) 1929 (71.4)
<60 ml/min/1.73 m2 — no. (%) 793 (29.6) 772 (28.6)
Index ACS — no. (%)
Myocardial infarction 2068 (77.2) 2084 (77.2)
Unstable angina requiring hospitalization 605 (22.6) 609 (22.5)
Missing data 6 (0.2) 8 (0.3)
Time between index ACS and randomization — days
Median 46 44
Interquartile range 31–64 30–65
* Plus–minus values are means ±SD. There were no significant differences between the two groups for any baseline char-
acteristic. ACS denotes acute coronary syndrome.
† The body-mass index is the weight in kilograms divided by the square of the height in meters.
‡ Race or ethnic group was self-reported.
§ Values include the index event of the acute coronary syndrome.
¶ The estimated glomerular filtration rate was calculated with the use of the Modification of Diet in Renal Disease formula.
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conduct or communication with those involved 
in study conduct.
The study then continued to the next group 
sequential analysis, which was performed after 
550 adjudicated primary end-point events had 
occurred, to rule out a hazard ratio of more than 
1.3. This analysis resulted in a hazard ratio of 0.96 
and an upper boundary of the one-sided repeated 
confidence interval of 1.17, findings that indicat-
ed noninferiority but not superiority of aloglip tin 
to placebo, and the conditional power for supe-
riority at 650 events was less than 20%; there-
fore, the data and safety monitoring committee 
recommended to the steering committee that the 
study be stopped. On March 9, 2013, the steering 
committee accepted the recommendation, and the 
sponsor agreed to stop enrollment in the study 
and proceed with a timely and orderly study 
closeout. The final date for evaluation of vital 
status was June 18, 2013.
R esult s
Study Patients
We recruited 5380 patients from 898 centers in 
49 countries (Fig. S1 in the Supplementary Ap-
pendix) from October 2009 through March 2013. 
At the date of the last patient visit (June 18, 2013), 
information on vital status was available for all 
but 25 patients (9 in the alogliptin group [0.3%] 
and 16 in the placebo group [0.6%]). The two 
study groups were well balanced with respect to 
baseline characteristics (Table 1) and nonstudy 
medications (Table 2). In the alogliptin group, 
on the basis of the estimated GFR at baseline, 
71.4% of the patients received 25 mg daily, 
25.7% received 12.5 mg daily, and 2.9% received 
6.25 mg daily. The rate of premature discontin-
uation of the study drug was similar in the alo-
gliptin and placebo groups (20.9% and 22.6% of 
patients, respectively). The median duration of 
exposure to aloglip tin was 533 days (interquar-
tile range, 280 to 751).
Changes in glycated hemoglobin levels over 
time are shown in Figure 1. By the end of the 
study period, the mean change from baseline 
was −0.33% in the alogliptin group and 0.03% 
in the placebo group, and the least-squares mean 
difference between the alogliptin group and the 
placebo group was −0.36 percentage points 
(95% confidence interval [CI], −0.43 to −0.28; 
P<0.001). The change from baseline in body 
weight was 1.09 kg with alogliptin and 1.04 kg 
with placebo, and the least-squares mean differ-
ence between the alogliptin group and the pla-
cebo group was 0.06 kg (95% CI, −0.25 to 0.36; 
P = 0.71). No significant differences in lipoprotein 
levels were observed between the two study groups 
(Table S2 in the Supplementary Appendix).
Primary and Secondary End Points
An additional 71 patients had a primary end-
point event after the 550-event interim analysis 
and just before the database was locked. For this 
complete analysis, the primary end point occurred 
at similar rates in the alogliptin and placebo 
Table 2. Exposure to Study Drugs and Proportions of Patients Receiving 
Nonstudy Medications.*
Variable
Placebo 
(N = 2679)
Alogliptin 
(N = 2701)
Receipt of study drug — no. (%) 2676 (99.9) 2698 (99.9)
Premature discontinuation of study 
drug — no. (%)
606 (22.6) 564 (20.9)
Because of adverse event,  
including death
275 (10.3) 270 (10.0)
Because patient declined to  
continue drug
192 (7.2) 169 (6.3)
Other reason 139 (5.2) 125 (4.6)
Duration of exposure to study drug
Median (interquartile range) — 
days
520 (273–744) 533 (280–751)
>1 Year of exposure to study drug 
— no. (%)
1787 (66.7) 1836 (68.0)
Medications administered at  
baseline — no. (%)
Antiplatelet agents 2602 (97.1) 2630 (97.4)
Aspirin 2433 (90.8) 2448 (90.6)
Thienopyridine 2165 (80.8) 2155 (79.8)
Beta-blockers 2203 (82.2) 2208 (81.7)
Statins 2420 (90.3) 2446 (90.6)
Antidiabetic agents 2649 (98.9) 2676 (99.1)
Insulin 812 (30.3) 793 (29.4)
Metformin 1805 (67.4) 1757 (65.0)
Thiazolidinediones 64 (2.4) 67 (2.5)
Sulfonylureas 1237 (46.2) 1266 (46.9)
Calcium-channel blockers 611 (22.8) 586 (21.7)
Diuretics 1009 (37.7) 1005 (37.2)
Renin–angiotensin system– 
blocking agents
2210 (82.5) 2201 (81.5)
* Diuretics included loop diuretics and thiazide diuretics. Renin–angiotensin 
system–blocking agents included angiotensin-converting–enzyme inhibitors 
and angiotensin II–receptor blockers.
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groups (in 11.3% and 11.8% of patients, respec-
tively, after a median exposure of 18 months; 
hazard ratio, 0.96; upper boundary of the one-
sided repeated CI, 1.16; P<0.001 for noninferior-
ity; P = 0.32 for superiority) (Table 3 and Fig. 2A). 
In the analysis of the components of the primary 
end point, the hazard ratios were consistent with 
the hazard ratio for the composite end point. The 
analysis of the principal secondary end point of 
death from cardiovascular causes, nonfatal myo-
cardial infarction, nonfatal stroke, or urgent re-
vascularization due to unstable angina showed 
no significant difference between the alogliptin 
group and the placebo group (12.7% and 13.4% 
of patients, respectively; hazard ratio, 0.95; upper 
boundary of the one-sided repeated CI, 1.14) (Ta-
ble 3, and Fig. S2 in the Supplementary Appen-
dix). Hazard ratios for death from any cause and 
death from cardiovascular causes (including 
deaths that occurred as primary end-point events 
and deaths that occurred after a nonfatal prima-
ry end-point event) were consistent with the haz-
ard ratio for the primary composite end point 
(Table 3 and Fig. 2B and 2C).
The subgroup analyses of the primary end 
point showed between-group heterogeneity in 
subgroups defined according to some of the 
baseline factors (Fig. S3 in the Supplementary 
Appendix). Subgroups in which there was nomi-
nally significant between-group heterogeneity 
included former smokers, patients who had had 
diabetes for at least 10 years, patients who were 
receiving insulin at baseline, patients who were 
not receiving biguanides at baseline, patients 
with moderate or severe renal impairment at 
baseline, and patients residing in North America 
or the region that included western Europe, Aus-
tralia, New Zealand, and the Middle East.
Adverse Events
The alogliptin and placebo groups did not differ 
significantly with respect to the incidence of seri-
ous adverse events (33.6% and 35.5%, respective-
ly; P = 0.14) (Table S3 in the Supplementary Ap-
pendix). The incidence of hypoglycemia was 
similar in the two study groups. The incidences 
of acute and chronic pancreatitis were similar in 
the two groups; no cases were fatal. There were 
no significant between-group differences in the 
incidence of cancer, and there were no reports of 
pancreatic cancer. The incidence of angioedema 
was low and did not differ significantly between 
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Figure 1. Least-Squares Mean Change from Baseline in Glycated Hemoglobin Levels over Time, According to Study 
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Data at 40 months were truncated owing to the small numbers of patients (eight per group). I bars indicate stan-
dard errors.
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the study groups. The proportion of patients 
with serum aminotransferase values three times 
the upper limit of the normal range at any time 
was similar in the alogliptin and placebo groups. 
Changes in estimated GFR according to baseline 
kidney function and incidences of initiation of 
dialysis were similar in the two study groups (Ta-
ble S3 and S4 in the Supplementary Appendix).
Discussion
This trial showed that treatment with the DPP-4 
inhibitor alogliptin resulted in rates of major car-
diovascular events that were similar to rates with 
placebo among patients with type 2 diabetes and 
substantial cardiovascular disease and cardiovas-
cular risk. The results of analyses of the individ-
ual components of the primary end point (death 
from cardiovascular causes, nonfatal myocardial 
infarction, and nonfatal stroke) and of analyses 
of deaths from any cause and all deaths from 
cardiovascular causes were consistent with those 
of the primary composite end point. The similar 
rates of the primary end point in the alogliptin 
and placebo groups were observed in the context 
of modestly better glycemic control in patients 
who received alogliptin. This finding is not sur-
prising in light of other trials that showed no 
effects of larger reductions in glycated hemoglo-
bin levels on similar end points over a period of 
5 years.4,5 However, the EXAMINE trial had a 
median duration of 18 months, and thus the re-
sults do not rule out longer-term benefits or risks 
of alogliptin with respect to cardiovascular end 
points.
Although DPP-4 inhibitors are in widespread 
clinical use for the treatment of type 2 diabe-
tes,16 their cardiovascular safety has not been 
established. The primary safety analysis in our 
trial determined the effects of alogliptin as com-
pared with placebo on a composite of major 
cardiovascular events that were adjudicated by 
an independent committee whose members 
were unaware of the study-group assignments. 
As compared with other cardiovascular safety 
 studies of various antidiabetic therapies,17-19 the 
 EXAMINE trial included patients at considerably 
higher cardiovascular risk, with event rates of 
more than 11% during the median follow-up 
period of 18 months. This trial showed no in-
crease in cardiovascular risk with alogliptin in 
this population during this median follow-up 
Table 3. Major Safety End Points.
End Point
Placebo 
(N = 2679)
Alogliptin 
(N = 2701)
Hazard Ratio for 
Alogliptin Group 
(95% CI) P Value*
no. (%)
Primary end point† 316 (11.8) 305 (11.3) 0.96 (≤1.16)‡ 0.32
Components of primary end point
Death from cardiovascular causes 111 (4.1) 89 (3.3) 0.79 (0.60–1.04) 0.10
Nonfatal myocardial infarction 173 (6.5) 187 (6.9) 1.08 (0.88–1.33) 0.47
Nonfatal stroke 32 (1.2) 29 (1.1) 0.91 (0.55–1.50) 0.71
Principal secondary end point§ 359 (13.4) 344 (12.7) 0.95 (≤1.14)‡ 0.26
Other end points
Death from any cause 173 (6.5) 153 (5.7) 0.88 (0.71–1.09) 0.23
Death from cardiovascular causes¶ 130 (4.9) 112 (4.1) 0.85 (0.66–1.10) 0.21
* P values for testing the superiority of alogliptin to placebo were calculated with the use of a Cox regression analysis.
† The primary end point was a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfa-
tal stroke.
‡ The parenthetical value is the upper boundary of the one-sided repeated CI, at an alpha level of 0.01.
§ The secondary end point was a composite of death from cardiovascular causes, nonfatal myocardial infarction, nonfatal 
stroke, or urgent revascularization due to unstable angina within 24 hours after hospital admission.
¶ Included are deaths that occurred as primary end-point events and deaths that occurred after a nonfatal primary end-
point event.
The New England Journal of Medicine 
Downloaded from nejm.org at ASTON UNIVERSITY on July 9, 2018. For personal use only. No other uses without permission. 
 Copyright © 2013 Massachusetts Medical Society. All rights reserved. 
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
n engl j med 369;14 nejm.org october 3, 20131334
period. Hence, for patients with elevated cardio-
vascular risk, including those with a recent acute 
coronary syndrome, who are likely candidates for 
the drug in clinical practice, it is reassuring that 
alogliptin does not increase cardiovascular morbid-
ity or mortality over a median period of 18 months.
There has been considerable speculation that 
DPP-4 inhibitors may exert beneficial effects on 
the cardiovascular system.20,21 Recent meta-
analyses of the clinical trial data have shown a 
lower risk of major cardiovascular events with 
DPP-4 inhibitors than with other classes of anti-
diabetic agents.11,22 However, the studies were 
limited by their short duration (<6 months in most 
cases), low event numbers, nonuniform and in-
complete ascertainment of cardiovascular end 
points, and comparisons of the DPP-4 inhibitors 
with both placebo and active agents, some of 
which have been associated with increased risk 
of cardiovascular disease and death from cardio-
vascular causes.7,23,24 In our trial, the rates of 
major adverse cardiovascular events were neither 
significantly increased nor significantly decreased 
with alogliptin, as compared with placebo, among 
patients who received appropriate standard-of-care 
treatment for type 2 diabetes and acute coronary 
syndromes.
The EXAMINE trial successfully adhered to 
the recommendations of the 2008 FDA guidance 
on the evaluation of new therapies for type 2 
diabetes.8 The nuances of the EXAMINE trial 
required a close interaction among the members 
of the steering committee, members of the data 
and safety monitoring committee, and represen-
Figure 2. Cumulative Kaplan–Meier Estimates of the 
Time to the First Adjudicated Occurrence of a Primary 
End-Point Event or Other Safety End Point.
Panel A shows the time to the first occurrence of a pri-
mary end-point event — death from cardiovascular 
causes, nonfatal myocardial infarction, or nonfatal 
stroke. After a median exposure of 18 months, the 
rates of the primary composite end point were similar 
in the alogliptin and placebo groups (11.3% and 
11.8%, respectively). Data at 40 months were truncat-
ed owing to the small numbers of patients (eight per 
group). Panel B shows the time to death from cardio-
vascular causes, and Panel C, the time to death from 
any cause. In each panel, the inset shows the same 
data on an enlarged y axis.
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tatives of the sponsor.12,25 The integrity of the 
trial was preserved during enrollment and follow-
up as well as during the months of study closeout 
because data were collected only by persons who 
were unaware of the results of interim analyses.
The noninferiority of alogliptin to placebo 
with respect to the primary end point was het-
erogeneous in six subgroups (P<0.05 for interac-
tion). These findings may have been due to 
chance, given the large number of tests per-
formed. Although the number of events contrib-
uting to these differences was small and the 
confidence intervals were large, these results 
raise questions as to whether differences among 
populations of patients or practice patterns in-
fluenced the effects of the randomly assigned 
study drugs. Further analyses will be required.
In conclusion, among patients with type 2 
diabetes and a recent acute coronary syndrome, 
treatment with alogliptin resulted in rates of 
death from cardiovascular causes, nonfatal myo-
cardial infarction, and nonfatal stroke that were 
similar to those with placebo. These data can be 
used to help guide clinicians in choosing among 
the many available antidiabetic agents when 
treating patients with type 2 diabetes and very 
high cardiovascular risk.
Supported by Takeda Development Center Americas.
Disclosure forms provided by the authors are available with 
the full text of this article at NEJM.org.
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